콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

Y0000009

Fluphenazine enantate

European Pharmacopoeia (EP) Reference Standard

동의어(들):

2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C29H38F3N3O2S
CAS Number:
Molecular Weight:
549.69
UNSPSC 코드:
41116107
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

fluphenazine

제조업체/상표

EDQM

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-8°C

SMILES string

FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCCN4CCN(CC4)CCOC(=O)CCCCCC

InChI

1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

InChI key

LRWSFOSWNAQHHW-UHFFFAOYSA-N

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Fluphenazine enantate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

픽토그램

Skull and crossbonesHealth hazard

신호어

Danger

유해 및 위험 성명서

예방조치 성명서

Hazard Classifications

Acute Tox. 3 Oral - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
G Chouinard et al.
The American journal of psychiatry, 139(3), 312-318 (1982-03-01)
Vitiligo-like syndrome following the use of fluphenazine enanthate.
M P Rampertaap
Missouri medicine, 82(1), 24-26 (1985-01-01)
M W Jann et al.
Clinical pharmacokinetics, 10(4), 315-333 (1985-07-01)
The clinical pharmacokinetics of the 4 depot antipsychotics for which plasma level studies are available (i.e. fluphenazine enanthate and decanoate, haloperidol decanoate, clopenthixol decanoate and flupenthixol decanoate) are reviewed. The proper study of these agents has been handicapped until recently
B M Cohen et al.
Journal of clinical psychopharmacology, 5(6), 328-332 (1985-12-01)
Depot forms of fluphenazine are frequently used in the outpatient treatment of psychiatric patients. To gather relevant data on pharmacokinetic characteristics of depot fluphenazines, the authors measured plasma levels of neuroleptic activity in 76 clinic patients on stable dosage regimens
J M Kane
The Journal of clinical psychiatry, 45(5 Pt 2), 5-12 (1984-05-01)
The use of long-acting injectable preparations such as fluphenazine enanthate or decanoate can reduce patient noncompliance, but documenting this in a controlled research design is difficult. Several studies of relapse rates among patients receiving oral fluphenazine, depot fluphenazine, or placebo

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.